secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001140361-23-053486
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.01, 5.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys enters $6.85M convertible note financing with warrants; three directors resign
--------------------------------------------------------------------------------

- Issued $6.85M principal of 6% senior unsecured convertible notes maturing Nov 2025; conversion price $1.18.
- Investors received Series A warrants (5.8M shares at $1.18, 1-year) and Series B warrants (5.8M shares at $1.475, 5-year).
- Keith Kendall, Anne Morrissey and Wendy Perrow resigned as directors effective Nov 8, 2023; Morrissey disagreed with no-dispute statement.
- PharmaCyte's interim CEO Joshua Silverman to join board; PharmaCyte gets nomination right until <5% ownership or note repaid.
- Nasdaq audit committee compliance temporarily lost after Kendall's resignation, restored by appointing Edward Uzialko.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123053486/0001140361-23-053486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123053486/ef20014760_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-053486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer